Clinical trials in biopharmaceutical R&D are increasingly resource-intensive due to outdated systems and poor data management, despite advancements in science. AI could revolutionize this process but is hindered by the lack of structured, clinically relevant data, necessitating a shift towards more sophisticated data infrastructure and governance frameworks.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





